Effectiveness of Protected Environment Rooms for AML and MDS

Stopped early

Conditions studied: Acute Myelogenous Leukemia, Myelodysplastic Syndrome

In brief

The goal of this clinical research study is to learn if the "protected environment" (PE) can help to prevent infections in patients aged 60 and above who are receiving what is considered low-intensity treatment for newly-diagnosed AML or high-risk MDS.

Key facts

Study ID

NCT00443300

Run by

M.D. Anderson Cancer Center

People needed

3

Starts

2007-01-01

Expected to finish

2008-01-01

Last updated by the study team

2012-08-02

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• AML or high-risk MDS (> 10% blasts in the marrow or blood)
• Patient is to be given "targeted therapy". Examples of targeted therapies are tipifarnib + low-dose ara-C, decitabine, and 5 azacitidine + valproic acid.
• Age >/= 60 years and Zubrod performance status of 0,1, or 2
• Informed consent obtained

You may not qualify if…

• Cannot receive ara-C at a dose >/= 100 mg/m2 daily, anthracyclines, or cloretazine.

Where it is running

• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.